Worldwide Angina Market Growing at CAGR of 5.1% by 2023 with Leading Players - Astellas Pharma, Torrent Pharmaceuticals Limited, Huya Bioscience International and more.

Global Angina Market Is Expected To Grow At An Approximate CAGR Of 5.1% During The Forecast Period.

Regional Analysis:

America dominates the global angina market owing to a well-developed healthcare sector, growing healthcare expenditure, and a huge patient population for coronary heart diseases. Moreover, global players such as Merck & Co., Inc. and Baxter within the region fuel the market growth.

Europe is the second largest market for angina. Factors such as availability of funds for research, growing number of obese and patient population, followed by the presence of developed economies such as France, Italy, and Germany within the region provide favorable backgrounds for regional market growth. According to the Eurostat in 2016, it was estimated that more than half of the adult population (51.6%) within the European Union was over-weight.

Access Sample Report @ https://www.marketresearchfuture.com/sample_request/5748 .

Asia Pacific is estimated to be the fastest growing region for the global angina market owing to the presence of developing economies such as India and China and a developing healthcare sector. Moreover, rising healthcare expenditure and favorable government policies are expected to boost the market growth during the forecast period.

The Middle East and Africa holds the least share in the global angina market, owing to the presence of poor economies, stringent government policies, and low per capita healthcare expenditure, especially within the African region. A majority of the market of the region is held by the Middle East owing to the increasing healthcare expenditure and presence of developed economies such as Saudi Arabia, Kuwait, and Qatar within the region.

Key Players:

Anthera (U.S.), Taxus Cardium (U.S.), Astellas Pharma (Japan), Sanofi (France), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Torrent Pharmaceuticals Limited (India), Huya Bioscience International (U.S.), Viromed Co. Ltd. (South Korea), Baxter (U.S.), and others.

Market Scenario

Angina is a significant symptom of the coronary artery disease and is described as squeezing, tightness, and heaviness of the chest. It is a type of chest pain, which is caused by a reduced flow of blood to the heart. Fatigue, shortness of breath, nausea, and sweating are some of the common symptoms of angina. The increasing prevalence of angina and the growing healthcare expenditure are the major drivers for the market growth. According to the report of the American Heart Association of 2016, the prevalence of angina in West Virginia was estimated to be around 6.2% and around 2.3% in Hawaii. Moreover, the growing geriatric and obese population followed by the increasing prevalence of coronary heart diseases provide favorable backgrounds for market growth. According to the World Health Organization, the total number of people who age 65 or more is projected to increase from 524 million in 2010 to approximately 1.5 billion by 2050. Additionally, according to a study published in the Annals of Translational Medicine Journal approximately 15.5 million people who aged 20 years or more within the U.S. suffered from the coronary heart disease, in 2016. However, factors such as low per capita healthcare expenditure and high cost for therapeutic procedures such as coronary bypass surgery are estimated to restraint the market growth during the forecast period. According to a study published by the Brazilian Journal of Cardiovascular Surgery in 2017, the average total cost for coronary bypass surgery was estimated to be ~USD 7,992.

Segmentation:

The global angina Market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into angina pectoris, unstable angina, prinzmetal angina, and others. On the basis of diagnosis, the market is categorized into imaging, blood test, stress test, and others. The imaging segment is sub-segmented into electrocardiogram, chest X-ray, cardiac computerized tomography scan, cardiac MRI, and others. The blood test segment is sub-segmented into cholesterol test, low-density lipoprotein test, triglycerides test, and others. On the basis of treatment, the market is segmented into lifestyle changes, medications, angioplasty and stenting, coronary bypass surgery, and others. The medication segment is sub-segmented into aspirin, clot-preventing drugs, statins, ranolazine, and others. The clot-preventing drugs segment is further segmented into clopidogrel, prasugrel, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, academic institutes, and others.

Table of Content:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

…Continued Full TOC

Get Discount @ https://www.marketresearchfuture.com/check-discount/5748 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.